Health Condition 1: E282- Polycystic ovarian syndrome
Conditions
Interventions
Intervention1: Tab Metformin 500 mg and Tab Myoinositol 600 mg: Tab Metformin 500 mg and Tab Myoinositol 600 mg both taken per oral after food twice a day for 3 months.
Intervention2: Group-B: Tab Met
Sponsors
Kalinga Institute of Medical Sciences
Eligibility
Inclusion criteria
Inclusion criteria: All Consenting Obese PCOS Female BMI more than equal to 25, Asia pacific guidelines, PCOS patients according to Rotterdam criteria with at least any one Cutaneous symptoms of moderate to severe variety like Acne with GAGS Score more than 18, Hirsutism with Modified Ferriman Gallwey Score more than 15, Female Pattern Hair Loss with Sinclair grade more than equal to 2 , Acanthosis Nigricans with Burke quantitative grade more than equal to 2)
Exclusion criteria
Exclusion criteria: Pregnant or Lactating Woman, Diagnosed case of any other Endocrine Disorder Congenital Adrenal Hyperplasia, Hyperprolactinemia, Hypothyroidism or Systemic disorder, Diabetes with Vascular Complications, Recent hormonal therapy, Hepatic/renal dysfunction, Smokers, Patients on drugs that may interfere with CHP metabolism (e.g., Rifampicin, griseofulvin).
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Metformin-Myoinositol may demonstrate Superiority in efficacy and safety than Metformin- Combined Hormonal Pill in the management of dermatological symptoms in obese PCOS patients.Timepoint: Metformin-Myoinositol may demonstrate Superiority in efficacy and safety than Metformin- Combined Hormonal Pill in the management of dermatological symptoms in obese PCOS patients. | — |
Secondary
| Measure | Time frame |
|---|---|
| NilTimepoint: Nil | — |
Countries
India
Contacts
Public ContactAshneet Kaur Anand
Kalinga Institute of Medical Sciences
Outcome results
None listed